HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bausch + Lomb Buy Vaults Valeant Into Consumer Eye Care Space

This article was originally published in The Tan Sheet

Executive Summary

Bausch + Lomb retains its name and becomes a division of Valeant in the $8.7 billion acquisition expected to close in the 2013 third quarter.

You may also be interested in...

Firms Sift Eye Study Data For Benefit From Lutein And Zeaxanthin

After the Age-Related Eye Disease Study found lutein, zeaxanthin and omega-3s do not slow age-related macular degeneration, supplement firms revisit the data and find lutein and zeaxanthin could slow the disease in deficient populations.

Valeant Includes OTCs In Bid For Dramatic Growth By 2013

The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.

Bausch & Lomb OcuVite Line Extension Used In Natl. Eye Institute Study

Promotions for Bausch & Lomb's new Ocuvite PreserVision containing vitamins C and E, beta carotene, zinc and copper likely will stress the product's clinically proven eye health benefits.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts